Detection of Canine Transitional Cell Carcinoma Using a Bladder Tumor Antigen Urine Dipstick Test

Veterinary Clinical Pathology

Volumn 28, Issue 1, 1999, Pages 33-38

  Borjesson, Dori L ^a   Christopher, Mary M ^a   Ling, Gerald V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dipstick; Dog; Transitional cell carcinoma; Tumor marker; Urine

Indexed keywords

CANIS FAMILIARIS;

EID: 0033464174     PISSN: 02756382     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-165X.1999.tb01039.x     Document Type: Article

References (17)

1. Norris AM, Laing EJ, Valli VE, et al: Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Int Med 6:145-153, 1992
2. Osborne CA, Low DG, Perman V: Neoplasms of the canine and feline urinary bladder: clinical findings, diagnosis and treatment. J Am Vet Med Assoc 152:247-259, 1968
3. DiBonito L, Musse MM, Dubine S, Falconieri G: Cytology of transitional cell carcinoma of the urinary bladder. Diag Cytopath 8:124-127, 1992
4. Raab SS, Lenel JC, Cohen MB. Low grade transitional cell carcinoma of the bladder. Cancer 74:1621-1626, 1994
5. Knapp DW, Richardson RC, Chan TCK, et al: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Int Med 8: 273-278, 1994
6. Knapp DW, Chan TCK, Kuczek T, et al: Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 56:801-805, 1995
7. Carpinito GA, Stadler WM, Briggman JV, et al: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urology 156:1280-1285, 1996
8. Pectasides D, Bafaloucos D, Antoniou F, et al: TPA, TATI, CEA, AFP, B-HCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 19:271-277, 1996
9. Allen DK, Waters DJ, Knapp DW, Kuczek T: High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer. J Vet Int Med 10:231-234, 1996
10. Pariente, JL, Bordenave L, Michel PH, et al: Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urology 158:338-341, 1997
11. Sarosdy MF, DeVere White RW, et al: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urology 154:379-384, 1995
12. Soloway MS, Briggman JV, Carpinito GA, et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical resection. J Urology 156:363-7, 1996
13. D'Hallewin MA, Baert, L: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urology 155:475-476, 1996
14. Leyh H, Mazemann E, et al: Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 50(1):49-53, 1997
15. Henry B: Clinical Diagnosis and Management by Laboratory Methods, 19th ed., pp. 422-423, WB Saunders, Philadelphia, PA, 1996
16. Sarosdy MF, Hudson MA, Ellis WJ et al: Improved detection of recurrent bladder cancer using the BARD BTA State test. Urology 50(3):349-353, 1997
17. Kinders RJ, Jones T, Root R, et al: Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family (abstract). J Urology 157: Suppl. 28, Abstract No, 110, 1997